Versartis, Inc. (VSAR) Given Average Rating of “Hold” by Analysts
Shares of Versartis, Inc. (NASDAQ:VSAR) have been given a consensus rating of “Hold” by the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.22.
Several brokerages recently issued reports on VSAR. ValuEngine cut Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Piper Jaffray Companies cut Versartis from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $26.00 to $4.00 in a research note on Friday, September 22nd. Barclays PLC cut Versartis from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $28.00 to $4.00 in a research note on Friday, September 22nd. Citigroup Inc. cut Versartis from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $23.00 to $3.00 in a research note on Monday, September 25th. Finally, BidaskClub cut Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th.
Versartis (NASDAQ:VSAR) opened at 2.45 on Wednesday. The stock’s market cap is $87.17 million. The stock has a 50 day moving average price of $8.77 and a 200-day moving average price of $15.41. Versartis has a 1-year low of $2.35 and a 1-year high of $24.00.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.20). On average, equities analysts expect that Versartis will post ($3.61) EPS for the current year.
In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Emory University purchased a new stake in Versartis during the second quarter worth $1,709,000. Credit Suisse AG lifted its holdings in Versartis by 28.0% during the first quarter. Credit Suisse AG now owns 27,066 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 5,917 shares during the period. Teachers Advisors LLC lifted its holdings in Versartis by 9.7% during the first quarter. Teachers Advisors LLC now owns 55,244 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 4,876 shares during the period. Vanguard Group Inc. lifted its holdings in Versartis by 11.3% during the first quarter. Vanguard Group Inc. now owns 1,002,507 shares of the biopharmaceutical company’s stock worth $21,404,000 after buying an additional 101,578 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in shares of Versartis during the 1st quarter valued at $563,000. Institutional investors own 73.61% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/25/versartis-inc-vsar-given-average-rating-of-hold-by-analysts.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.